Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Exagen Inc. (XGN)
Last exagen inc. earnings: 3/25 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights. Three Months Ended December 31, Year Ended December 31, 2025 2025(in thousands, except ASP data) Revenue$16,631 $66,575 Gross margin 55.4% 58.3%Operating expenses$14,181 $52,869
Show less
Read more
Impact Snapshot
Event Time:
XGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XGN alerts
High impacting Exagen Inc. news events
Weekly update
A roundup of the hottest topics
XGN
News
- Exagen (XGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=XGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell".MarketBeat
- Exagen (XGN) had its price target lowered by Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Exagen (XGN) had its price target lowered by Craig Hallum from $12.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Exagen (XGN) had its price target lowered by KeyCorp from $15.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Avolta AG GAAP EPS of CHF 1.36, revenue of CHF 13.76B [Seeking Alpha]Seeking Alpha
XGN
Earnings
- 3/10/26 - In-Line
XGN
Sec Filings
- 3/16/26 - Form 3
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- XGN's page on the SEC website